FINWIRES · TerminalLIVE
FINWIRES

Update: Market Chatter: Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug

-- (Updates with Merck's response to a request for comment from.)

Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported Wednesday, citing people familiar with the matter.

Inhibrx is exploring a joint spin-off of the treatment, INBRX-106, as well as a second experimental cancer drug, which could have a combined value of more than $9 billion if clinical trials succeed, the people told Reuters.

Inhibrx and Merck declined to comment to, while Ono Pharmaceutical didn't immediately reply to a request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $112.63, Change: $+0.07, Percent Change: +0.06%

相关文章

Asia

Downer EDI发行的4亿澳元高级无抵押债券获得惠誉“BBB”评级。

据信用评级机构惠誉周五发布的报告显示，Downer EDI（澳交所代码：DOW，新西兰证券交易所代码：DOW）发行的4亿澳元、票面利率为6.488%的2033年4月到期高级无抵押债券获得“BBB”评级。 惠誉表示，此次评级的主要驱动因素包括Downer受中东冲突引发的成本压力影响较小、自由现金流恢复以及预期公司利润率将持续回升等。 关键评级假设包括：在出售非核心业务后，惠誉定义的收入在2026财年下降约5%，随后从2027财年至2029财年平均每年增长3%。 Downer EDI的澳大利亚股价在周五的交易中下跌了1%。

$ASX:DOW$NZE:DOW
Asia

深南电路第一季度利润飙升73%，营收增长38%

根据深圳证券交易所周五发布的公告，深南电路板（SHE:002916）第一季度归属于股东的净利润同比增长73%，从去年同期的4.914亿元人民币增至8.502亿元人民币。 每股收益同比增长32%，从去年同期的0.96元人民币增至1.27元人民币。 营业收入同比增长38%，从去年同期的47.8亿元人民币增至66亿元人民币。 这家印刷电路板制造商的股价在周五上午的交易中下跌超过1%。

$SHE:002916
Asia

SPIC 2025年利润下滑1%，营收增长2%；股价下跌3%

根据周五提交深圳证券交易所的公告，国家电力投资集团（SPIC Industry-Finance，股票代码：000958）2025年归属于股东的净利润同比下滑0.7%至32.9亿元人民币，即每股0.2541元人民币。 上年同期归属于股东的净利润为33.2亿元人民币，即每股0.2558元人民币。 总营业收入同比增长1.9%至125亿元人民币，高于上年的122亿元人民币。 这家中国供热供电服务提供商的股价在早盘交易中下跌超过3%。

$SHE:000958